Cikarang, Bekasi, October 10, 2016 - PT Kimia Farma (Persero) Tbk (KF) made a new history by constructing a raw materials plant for drugs or Active Pharmaceutical Ingredient (API).

Previously, KAEF has built a plant of pharmaceutical salt raw materials phase I, which is now 100% completed and will be continued of the second phase construction at this year with a larger capacity.
As a follow up of the cooperation with the establishment of a Joint Venture (JV) Company between KF with PT Indonesia Sungwun Pharmacopia Pharmacopia representatives of Sungwun Co. Ltd. of South Korea, namely the establishment of a new subsidiary company PT Kimia Farma Sungwun Pharmacopia on January 25, 2016, on this day will be the start of construction of the sign Groundbreaking Drug Raw Material Factory (API) which is located on Jl. Angsana Raya Blok A 06-001, Delta Silicon 1, Industrial Area Lippo Cikarang, Bekasi area of ​​5,000 m2 of 6 hectares provided.
The factory is built according to the standards of Good Manufacturing Practice (GMP) and is expected to be completed by the end of 2017. As for the commercialization of the production of Active Pharmaceutical Raw Materials (API) is planned in early 2018.
To date, the type of Raw Material Drugs that will be produced there are 8 (eight) items, namely: Simvastatin, Atorvastatin, Rosuvastatin, Pantoprazole, esomeprazole, rabeprazole, clopidogrel and Sarpogrelate with a total production capacity of 30 tons per year. Drug Raw Materials Production is to meet 100% of the entire pharmaceutical industry in Indonesia for the last eight of the raw materials and the rest for export markets.
In addition to producing Active Pharmaceutical Raw Materials (API), the plant will also produce the High Function Chemical (HFC) which can be used as raw material for cosmetics and food supplement, which all results HFC products will be exported to Korea, Japan and America.
This is in line with the Government Programme, namely Independence Program National Drug Raw Materials contained in the Roadmap Ministry of Health and supported by the Economic Policy Package XI and Presidential Instruction No. 6 Year 2016 on Accelerating the Development of the Pharmaceutical Industry and Medical Devices, KF are optimistic that the dependence on imports Drug Raw Materials (API) will start to decrease in the future and eventually Indonesia capable of self-sufficient in the production of Drug Raw Materials.
KF cooperating partners work together with South Korea, Sungwun Pharmacopia Co., Ltd, because they have the technology to produce Drug Raw Materials (API) as well as to transfer technology and transfer of knowledge about the production Drug Raw Materials, by providing training in South Korea for 1 ( one) year for the entire human resources working in this factory, which will start later this year. In addition, the South Korean side also guarantees the purchase of products with take or pay system, on the whole the results of the products, as they already have quite extensive market network, namely in Japan and America.
With the transfer of technology and knowledge transfer, is expected to Indonesia in the future may have the ability to develop independently Drug Raw Materials to carry out research and development, in particular for the development of Drug Raw Materials.


grafik KAEF.JK
2.390 (+1,70%)
Prev Close : 2.350
Volume : 31.800
BPOMLogo Badan POM kemenbumnlogo Kementerian BUMN
Kemenkeslogo Kementerian Kesehatan beilogo PT. Bursa Efek Jakarta